Organo Gold International, Inc. – Trademark Portfolio
Entity Type: 03
Organo Gold International, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include CNS90, FENIX CXT, and COFFEE CONNOISSEUR. The owner is based in Blaine, WA.
2390 Peace Portal Drive #270
Blaine, WA 98230
Showing of trademarks Trademarks
Trademark Classifications
Organo Gold International, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Organo Gold International, Inc. have?
Organo Gold International, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 3 registered, 3 abandoned.
What trademark classes does Organo Gold International, Inc. file in?
Organo Gold International, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Organo Gold International, Inc.'s most well-known trademarks?
Organo Gold International, Inc.'s registered trademark portfolio includes well-known marks such as CNS90, FENIX CXT, and COFFEE CONNOISSEUR. These are among 3 currently registered trademarks in the portfolio.
What is Organo Gold International, Inc.'s trademark registration success rate?
Organo Gold International, Inc. has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.